Abstract
BACKGROUND: To develop a predictive model using baseline imaging of morphology and radiomics derived from intravoxel incoherent motion diffusion-weighted imaging (IVIM-DWI) to determine the pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) in breast cancer patients. METHODS: A total of 265 patients who underwent 3.0 T MRI scans before NACT were examined. Among them, 113 female patients with stage II-III breast cancer were included. The training data set consisted of 79 patients (31/48=pCR/Non-PCR, npCR), while the remaining 34 cases formed the validation cohort (13/21=pCR/npCR). Radiomics and conventional magnetic resonance imaging features analysis were performed. To build a nomogram model that integrates the radiomics signature and conventional imaging, a logistic regression method was employed. The performance evaluation of the nomogram involved the area under the receiver operating characteristic curve (AUC), a decision curve analysis, and the calibration slope. RESULTS: In an assessment for predicting pCR, the radiomics model displayed an AUC of 0.778 and 0.703 for the training and testing cohorts, respectively. Conversely, the morphology model exhibited an AUC of 0.721 and 0.795 for the training and testing cohorts, respectively. The nomogram displayed superior predictive discrimination with an AUC of 0.862 for the training cohort and 0.861 for the testing cohort. Decision curve analyses indicated that the nomogram provided the highest clinical net benefit. CONCLUSION: Performing a nomogram consisting of integrated morphology and radiomics assessment using IVIM-DWI before NACT enables effective prediction of pCR in breast cancer. This predictive model therefore can facilitate medical professionals in making individualized treatment decisions.